Morena Miciaccia

Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery

AbstractOvarian cancer is the most lethal gynecological cancer, with a survival rate of approximately 40% at five years from the diagno. The first‐line treatment consists of cytoreductive surgery combined with chemotherapy (platinum‐ and taxane‐based drugs). To date, the main prognostic factor is related to the complete surgical resection of tumor lesions, including occult micrometastases. The presence of minimal residual diseases not detected by visual inspection and palpation during surgery significantly increases the risk of disease relapse. Intraoperative fluorescence imaging systems have the potential to improve surgical outcomes. Fluorescent tracers administered to the patient may support surgeons for better real‐time visualization of tumor lesions during cytoreductive procedures. In the last decade, consistent with the discovery of an increasing number of ovarian cancer‐specific targets, a wide range of fluorescent agents were identified to be employed for intraoperatively detecting ovarian cancer. Here, we present a collection of fluorescent probes designed and developed for fluorescence‐guided ovarian cancer surgery. Original articles published between 2011 and November 2022 focusing on fluorescent probes, currently under preclinical and clinical investigation, were searched in PubMed. The keywords used were targeted detection, ovarian cancer, fluorescent probe, near‐infrared fluorescence, fluorescence‐guided surgery, and intraoperative imaging. All identified papers were English‐language full‐text papers, and probes were classified based on the location of the biological target: intracellular, membrane, and extracellular.